Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease

Starting soon

Conditions studied: Psoriasis, Psoriasis Arthritis, Psoriasis (PsO)

In brief

The goal of this observational registry study is to evaluate the real-world effectiveness and safety of IL-23 inhibitors in patients with psoriatic disease (psoriasis and/or psoriatic arthritis) treated in Costa Rica. The main questions it aims to answer are: * Do IL-23 inhibitors (guselkumab or risankizumab) improve disease severity and quality of life in patients with psoriatic disease in routine clinical practice? * What is the safety profile and treatment persistence of IL-23 inhibitors in this population? * Patients receiving IL-23 inhibitors as part of their usual medical care will be followed longitudinally using standardized clinical measures (e.g., PASI, DLQI, DAPSA/BASDAI) and adverse-event reporting through a national registry.

Key facts

Study ID

NCT07448402

Run by

Caja Costarricense de Seguro Social

People needed

50

Starts

2026-05-01

Expected to finish

2031-05-01

Last updated by the study team

2026-03-09

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of psoriatic disease, including psoriasis (any clinical variant) and/or psoriatic arthritis based on rheumatologic criteria.
• Receiving IL-23 inhibitor therapy (guselkumab or risankizumab).
• Treated within participating Costa Rican public health centers.
• Availability of sufficient clinical records to complete registry data (history, follow-up, labs).
• Age ≥12 years, any sex.

You may not qualify if…

• None specified (all patients meeting inclusion criteria are eligible).

Where it is running

• Caja Costarricense del Seguro Social — San José, Provincia de San José, Costa Rica

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.